Tempest Therapeutics Inc. diskutieren

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its price target lowered by analysts at Piper Sandler from $10.00 to $6.00. They now have an "overweight" rating on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its price target raised by analysts at HC Wainwright from $35.00 to $47.00. They now have a "buy" rating on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its "outperform" rating re-affirmed by analysts at William Blair.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.

Tempest Therapeutics, Inc. (NASDAQ: TPST) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $8.00 price target on the stock.

Tempest Therapeutics is an exciting clinical-stage oncology company developing innovative therapies that harness both targeted and immune-mediated mechanisms. Their lead candidate, amezalpat (TPST-1120), has shown promising results in a randomized Phase 1b/2 study for first-line treatment of hepatocellular carcinoma, demonstrating a significant improvement in median overall survival compared to the control arm. This positive data, coupled with recent insider buying activity, suggests that Tempest could be on the cusp of a breakthrough. While the stock is currently trading at $2.032, the potential upside based on the new survival data and insider confidence makes Tempest an intriguing investment opportunity worth considering. As with any biotech stock, there are inherent risks, but the company's innovative approach and the positive clinical results so far make this a stock worth keeping an eye on.

Tempest Therapeutics is an exciting biotech company that has caught my attention. They're developing innovative cancer treatments that combine targeted and immune-mediated mechanisms, and their latest data on amezalpat (TPST-1120) in first-line hepatocellular carcinoma is quite promising. The fact that insiders are buying up shares is also a good sign - they must see significant potential in the company's pipeline. While the stock is currently trading at around $2, I believe it has the opportunity to reach $4.50 or more in the coming year as their therapies progress through clinical trials and potentially gain regulatory approvals. Of course, investing in biotech carries inherent risks, but Tempest's approach and the insider buying activity make this an intriguing prospect worth further research. What do you think - does this sound like a stock you might want to keep an eye on?

Tempest Therapeutics is an up-and-coming player in the oncology space, and their recent developments have piqued my interest. The news of their lead candidate, amezalpat (TPST-1120), delivering a significant improvement in overall survival for first-line hepatocellular carcinoma (HCC) patients is very promising. If this data holds up in further studies, it could be a game-changer for Tempest and provide a much-needed treatment option for a disease with limited effective therapies. Additionally, the recent insider buying activity by the Chief Medical Officer and Corporate Controller suggests they see value in the company's prospects. While the current share price of $2.032 may seem low, I believe Tempest has the potential to deliver long-term returns for investors willing to take on the risks associated with a clinical-stage biotech. Of course, there are always uncertainties with drug development, but the positive data and insider confidence make me optimistic about Tempest's future. What do you think - does this sound like an opportunity worth exploring further?

Tempest Therapeutics is an exciting biotech company with promising oncology drug candidates in its pipeline. The recent positive data from the Phase 1b/2 study of amezalpat (TPST-1120) in first-line hepatocellular carcinoma (HCC) treatment is particularly encouraging, showing a significant survival benefit over the control arm. This, combined with insider buying activity, suggests that the company may be on the cusp of a breakthrough. While the stock is currently trading at a relatively low price, I believe it has the potential to climb higher as the company continues to deliver positive clinical results and advances its pipeline. As with any biotech investment, there are risks, but the upside potential seems to outweigh the downside at this point. I'm optimistic about Tempest Therapeutics' future and think it's worth considering adding this stock to your portfolio.

Tempest Therapeutics is an exciting biotech company with promising cancer treatment candidates in its pipeline. The recent positive data for their lead drug amezalpat (TPST-1120) in a first-line hepatocellular carcinoma (HCC) study is particularly encouraging, showing a significant survival advantage over the control arm. This kind of breakthrough could be a game-changer for HCC patients. Additionally, the insider buying activity is a positive signal, suggesting that company insiders are bullish on the stock's prospects. While the current share price of $1.907 may seem low, I believe Tempest has significant upside potential as they continue to advance their clinical programs. With a strong pipeline and promising data, Tempest could emerge as a leader in the oncology space. Of course, investing in any biotech company carries risks, but I'm optimistic about Tempest's future and believe the stock is worth considering at this level.